An interventional study of IMST and Sham Training in Chronic Kidney Diseases, Hypertension and Aging, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Renal Insufficiency, Chronic by University of Colorado, Denver — 6 open to participants now, 8 under way, 1 of them phase 3. Renal Insufficiency, Chronic · University of Colorado, Denver.
Among the 21 studies in Renal Insufficiency, Chronic by University of Colorado, Denver, this one is the 8th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 8 with no phase, and was the 16th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 21 studies in Renal Insufficiency, Chronic by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18–75
University of Colorado, Denver · Sites in United States
Ages 50+ · Women only
University of Colorado, Denver · Sites in United States
Ages 18 mo–25 yrs
University of Colorado, Denver · Sites in United States
Ages 50–69 · Women only · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 86 across the 18 interventional studies, 90 across the 3 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06128278University of Colorado, DenverAcute Equol Supplementation and Vascular Function in Women With and Without CKD | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Renal Insufficiency, Chronic by University of Colorado, Denver, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
More than 80% of individuals with chronic kidney disease have concomitant hypertension and the majority fail to achieve blood pressure control \<130/80 mmHg, leading to high risk of cardiovascular diseases and end-stage kidney disease. A stepwise combination of lifestyle modifications and drug therapy is recommended to lower blood pressure; however, adherence to time-intensive lifestyle interventions such as aerobic exercise in patients with chronic kidney disease is poor. This clinical trial seeks to establish the efficacy of high-resistance inspiratory muscle strength training, a novel time-efficient lifestyle intervention, for lowering systolic blood pressure and improving endothelial function in midlife and older adults with moderate-to-severe chronic kidney disease and inadequately controlled hypertension, and to use innovate translational assessments to understand the mechanisms involved.
Chronic kidney disease (CKD) is a major public health concern that has reached epidemic proportions. Hypertension is a leading modifiable risk factor for cardiovascular disease (CVD) and end-stage kidney disease, yet 50-70% of adults with CKD fail to achieve blood pressure (BP) control to \<130/80 mmHg. A key process linking high systolic BP (SBP) to CVD is vascular endothelial dysfunction, which is due in part to increased reactive oxygen species and decreased nitric oxide. Nitric oxide is also critical in the regulation of renal blood flow, which is intimately related to blood pressure and vascular function. High-resistance inspiratory muscle strength training (IMST) is a novel lifestyle intervention involving repeated inhalations against a resistive load using a hand-held device. This study will test whether high-resistance IMST (75% of maximal inspiratory pressure [75% PImax]; 30 breaths [5 min]/day, 6 days [30 min]/week) vs. Sham training (15% PImax) reduces resting systolic blood pressure in midlife and older adults (>50 years) with moderate-to-severe CKD and inadequately controlled hypertension. Changes in 24-hr systolic blood pressure and endothelial function (brachial artery flow-mediated dilation) are secondary outcomes. Innovative translational techniques will be used to provide mechanistic insight, including serum incubation in endothelial cell culture, metabolomics analysis, endothelial cell collections, and assessment of renal blood flow by magnetic resonance imaging. Changes and cerebrovascular and cognitive function will be assessed as part of a sub-study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will perform high-resistance (75% of maximal inspiratory pressure) inspiratory muscle strength training (IMST), 30 inhalations/session, 6 days/week.
Device: IMST
This group will perform low-resistance (15% of maximal inspiratory pressure) inspiratory muscle strength training, 30 inhalations/session, 6 days/week.
Device: Sham Training
Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
Repeated inhalations against a low resistance will be performed using a handheld device.
Change in Casual Systolic Blood Pressure
Casual (resting) measures of systolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer.
Time frame: Baseline, 3 months
Change in 24-Hour Ambulatory Systolic Blood Pressure
Brachial artery systolic blood pressure (mmHg) will be measured automatically every 20 minutes for a 24-hour period by an ambulatory blood pressure monitor and will be averaged over the entire 24-hour period.
Time frame: Baseline, 3 months
Change in Brachial Artery Flow-Mediated Dilation
Flow-mediated dilation of the brachial artery will be performed using ultrasonography and analyzed with a commercially available software package as percent change in diameter from baseline following reactive hyperemia.
Time frame: Baseline, 3 months
Change in Ex Vivo Nitric Oxide Production
Human umbilical vein and/or cerebral endothelial cells will be incubated with basal media supplemented with 10% human serum collected from participants and stained with the fluorescent probe DAF-FM diacetate to detect nitric oxide production production in response to acetylcholine.
Time frame: Baseline, 3 months
Change in Ex Vivo HUVEC eNOS Activation
Human umbilical vein and/or endothelial cells will be treated with 10% human serum and protein expression of cell lysates will be determined by capillary electrophoresis immunoassay.
Time frame: Baseline, 3 months
Change in Ex Vivo Reactive Oxygen Species Production
Human umbilical vein endothelial cells will be incubated with basal media supplemented with 10% human serum collected from participants and stained with the fluorescent probe CellROX Deep Red to detect reactive oxygen species production.
Time frame: Baseline, 3 months
Change in Endothelial Cell Protein Expression of MnSOD
In a sub-group of participants, endothelial will be obtained from peripheral veins via endovascular biopsy, recovered by centrifugation, fixed, and analyzed for protein expression of MnSOD in collected endothelial cells relative to human umbilical vein endothelial cells using immunofluorescence.
Time frame: Baseline, 3 months
Change in Endothelial Cell Protein Expression of NADPH oxidase
In a sub-group of participants, endothelial will be obtained from peripheral veins via endovascular biopsy, recovered by centrifugation, fixed, and analyzed for protein expression of NADPH oxidase in collected endothelial cells relative to human umbilical vein endothelial cells using immunofluorescence.
Time frame: Baseline, 3 months
Change in Endothelial Cell Abundance of Nitrotyrosine
In a sub-group of participants, endothelial will be obtained from peripheral veins via endovascular biopsy, recovered by centrifugation, fixed, and analyzed for abundance of nitrotyrosine in collected endothelial cells relative to human umbilical vein endothelial cells using immunofluorescence.
Time frame: Baseline, 3 months
Change in Renal Blood Flow
Magnetic resonance imaging will be used to determine flow of the renal arteries.
Time frame: Baseline, 3 months
Adherence
Adherence will be evaluated as percent of completed training sessions at the required workload using data stored on the training device.
Time frame: 3 months
Safety (adverse events)
Safety will be evaluated as the number of participants with treatment-related adverse events in each group.
Time frame: 3 months
Tolerability (drop-out due to adverse events)
Tolerability will assessed as the rate at which enrolled subjects drop out due to adverse events.
Time frame: 3 months
Change in Casual Diastolic Blood Pressure
Casual (resting) measures of diastolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer.
Time frame: Baseline, 3 months
Change in 24-Hour Ambulatory Diastolic Blood Pressure
Brachial artery diastolic blood pressure (mmHg) will be measured automatically every 20 minutes for a 24-hour period by an ambulatory blood pressure monitor and will be averaged over the entire 24-hour period.
Time frame: Baseline, 3 months
Change in Endothelium-Independent Dilation
Endothelium-independent dilation will be determined using ultrasonography and analyzed with a commercially available software package as percent chance in brachial artery diameter following 0.4 mg of sublingual nitroglycerin.
Time frame: Baseline, 3 months
Change in middle cerebral artery cerebrovascular reactivity
Change in middle cerebral artery velocity in response to hypercapnia
Time frame: Baseline, 3 months
Change in internal carotid artery cerebrovascular reactivity
Internal carotid artery diameter in response to hypercapnia
Time frame: Baseline, 3 months
Change in middle cerebral artery pulsatility index
Pulsatility index of the middle cerbral artery via transcranial doppler
Time frame: Baseline, 3 months
Change in brain blood flow
Total brain blood flow measured via ultrasonography of the internal carotid and vertebral arteries
Time frame: Baseline, 3 months
Change in NIH toolbox cognitive function
Total composite score using the NIH toolbox exam
Time frame: Baseline, 3 months
Change in executive function
Time to complete the trailmaking test part B
Time frame: Baseline, 3 months
Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in CKD. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. data use agreement) are prerequisites to the sharing of data with the requesting party.
Supporting information: Study protocol, Informed consent form
Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Jul 2026, 52 months after the start.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 52 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
University of Colorado, Denver →